Conjugation of the monoclonal antibody 17-1A with the nitroacridine compound C921 with the poly-L-lysine as an intermediate agent.
Monoclonal antibody 17-1A specific for human gastric carcinoma was coupled directly or indirectly, using poly-L-lysine as an intermediate, with nitroacridine compound C921. The aim of the study was to obtain selectively cytotoxic immunoconjugates for experimental therapy. Directly coupled conjugates retained antibody specificity towards cells of several human adenocarcinoma lines but were non cytotoxic in vitro, whereas conjugates obtained with the use of intermediate poly-L-lysine expressed only low, non-specific cytotoxicity, probably exerted by the poly-L-lysine content.
Paprocka
M
M
Department of Tumor Immunology, Polish Academy of Sciences, Wrocław, Poland.
Boratyński
J
J
Duś
D
D
Kuśnierczyk
H
H
Radzikowski
C
C
D000166:Acridines / Q000737:chemistry / Q000494:pharmacology*; D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology; D000918:Antibody Specificity; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000276:immunology; D005434:Flow Cytometry; D006801:Humans; D000922:Immunotoxins / Q000737:chemistry* / Q000494:pharmacology*; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology; D011107:Polylysine / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000166:Acridines; D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D011107:Polylysine